Track market-moving stories before they get noisy

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of The Cooper Companies, Inc. ("Cooper" or the "Company") (NASDAQ: COO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Cooper and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 9, 2026, Cooper announced third quarter 2026 results.  Among other things, the Company "reported revenue of $717 million, essentially flat year-over-year" and said that "the results in the Americas reflected CooperVision' U.S. channel inventory reductions."  The Company further stated that it "proactively reduced U.S. channel inventory that weighed on our results and will continue to impact Q4."  Cooper also lowered its full-year guidance, explaining that "the entire reason for the reduction in the revenue guidance for CooperVision was tied to just channel inventory."  Cooper also reduced revenue guidance by approximately 1.4%, or $59.5 million at the midpoint, to $4.24 billion, and likewise reduced EPS guidance by approximately 1.8%, or $0.09 at the midpoint, to a range of $4.51 to $4.55.  

On this news, Cooper's stock price fell $9.31 per share, or 14.67%, to close at $54.17 per share on September 10, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.  

CONTACT:

Danielle Peyton

Pomerantz LLP

[email protected]

646-581-9980 ext. 7980

SOURCE Pomerantz LLP

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of The Cooper Companies, Inc. (NASDAQ: COO) resulting from allegations that Cooper Companies may have issued materially misleading business information to the investing public.

So What: If you purchased Cooper Companies securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/cases/the-cooper-companies-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On September 10, 2026, The Motley Fool published an article entitled "Why is Cooper Companies Stock Down 15% Today?". The article stated that Cooper Companies stock fell "after the company's earnings report disappointed Wall Street with weak guidance and a decision to not sell CooperSurgical."

On this news, Cooper Companies's stock fell 14.6% on September 10, 2026.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions.  Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY 10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

LOS ANGELES, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of The Cooper Companies, Inc. (“Cooper Companies” or the “Company”) (NASDAQ: COO) investors concerning the Company’s possible violations of the federal securities laws.

IF YOU ARE AN INVESTOR WHO LOST MONEY ON THE COOPER COMPANIES, INC. (COO) CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

What Happened?
On September 9, 2026, Cooper Companies announced third quarter 2026 results. Among other things, the Company “reported revenue of $717 million, essentially flat year-over-year” and stated that “the results in the Americas reflected CooperVision’s U.S. channel inventory reductions.” The Company further stated that it “proactively reduced U.S. channel inventory that weighed on our results and will continue to impact Q4.” Cooper also lowered its full-year guidance, explaining that “the entire reason for the reduction in the revenue guidance for CooperVision was tied to just channel inventory.” Revenue guidance was reduced by approximately 1.4%, or $59.5 million at the midpoint, to $4.24 billion, while EPS guidance was reduced by approximately 1.8%, or $0.09 at the midpoint, to a range of $4.51 to $4.55.

On this news, Cooper Companies shares declined $9.31 or 14.67% per share, to close at $54.17 on September 10, 2026, thereby injuring investors.

Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles H. Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email:  [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

Whistleblower Notice
Persons with non-public information regarding Cooper Companies should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email [email protected].

About Glancy Prongay Wolke & Rotter LLP
Glancy Prongay Wolke & Rotter LLP (“GPWR”) is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPWR has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPWR was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements.

With four offices across the country, GPWR’s nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPWR’s lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPWR’s past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron’s, Investor’s Business Daily, Forbes, and Money.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles H. Linehan
Email:  [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

It has been about a month since the last earnings report for The Cooper Companies (COO - Free Report) . Shares have added about 0.2% in that time frame, underperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is The Cooper Companies due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.

COO Q3 Earnings Top Estimates, Revenues Miss on DestockingThe Cooper Companies reported third-quarter fiscal 2026 adjusted earnings per share of $1.15, up 4.5% year over year. The figure beat the Zacks Consensus Estimate of $1.11 by 3.6%, aided by expense management and productivity initiatives.

GAAP earnings per share for the quarter was $2.24, significantly up from the year-ago period’s figure of 49 cents, primarily driven by a $307.2 million discrete tax benefit following the favorable completion of a U.K. tax examination.

COO’s fiscal third-quarter revenues rose 0.6% year over year to $1.066 billion but missed the Zacks Consensus Estimate of $1.099 billion by 3.0%. The quarterly revenues were up 1% year over year at the constant exchange rate (CER). U.S. CooperVision channel inventory reductions weighed on sales. MiSight remained a bright spot, delivering 20% organic growth.

COO's CooperVision Segment Faces Inventory PressureFor the third quarter of fiscal 2026, CVI revenues were $717.0 million, flat year over year on a reported, CER and organic basis. The segment faced pressure from proactive U.S. channel inventory reductions, which offset underlying demand and strength in several premium product categories.

Category-wise, CVI derives revenues from Toric and multifocal, Sphere and others.

Toric and multifocal revenues were $363.8 million, up 1% year over year and 2% at CER as well as organically. Sphere and other revenues totaled $353.2 million, declined 2% year over year on a reported basis and fell 1% at CER as well as organically. MyDay toric, MyDay multifocal and MyDay Energys each recorded double-digit growth, while MiSight maintained strong momentum.

COO's CooperSurgical Segment Growth Holds FirmIn the third quarter of fiscal 2026, CSI revenues were $349.2 million, up 2% year over year on a reported basis as well as at CER and grew 3% organically.

Category-wise, CSI derives revenues from Office and Surgical, and Fertility.

Office and Surgical revenues were $208 million, up 2% on a reported and organic basis as well as at CER. Medical Devices grew 4%, driven by strength in surgical OB/GYN and specialty device portfolios, while Paragard revenues were flat. Management continued to point to genomics and adoption of the Witness automated laboratory management platform as contributors to fertility performance.

Fertility revenues were $141.2 million, up 3% year over year on a reported basis, up 4% at CER with organic growth of 5%, supported by broad-based strength across products and services, new clinic wins and expansion within existing accounts.

COO's Geographic Results Show a Mixed TrendGeographically, growth was led by the Americas, while EMEA and Asia Pac remain mixed as strength across several markets was offset by macro headwinds in the Middle East and China.

Within CVI, Americas revenues totaled $281.6 million, down 2% year over year on a reported basis, at CER and organically. The weakness reflected the company's decision to reduce U.S. channel inventory. Management noted that Americas revenues would have grown around 5% without the inventory actions, while underlying U.S. consumption remained at a mid-single-digit growth rate.

EMEA revenues were $309.4 million, up 6% year over year on a reported basis and 5% at CER as well as organically, supported by continued strength across premium offerings. Asia Pacific revenues totaled $126 million, down 10% on a reported basis and 5% at CER and organically, with portfolio rationalization and softer conditions in certain markets weighing on performance.

COO’s Q3 Margin TrendIn the quarter under review, Cooper Companies’ adjusted gross profit declined 0.3% year over year to $711.1 million. The adjusted gross margin was 66.7%, down 60 basis points (bps) from the year-ago period, reflecting higher manufacturing costs and unfavorable foreign exchange.

Selling, general and administrative expenses decreased 4.8% to $401.3 million. Research and development expenses fell 6.7% to $41.6 million. Adjusted operating costs totaled $430.4 million, reflecting a 1.5% decrease from the prior-year quarter’s level.

Adjusted operating profit totaled $280.7 million, up 1.6% from the year-earlier quarter’s level. The adjusted operating margin expanded 30 bps to 26.3%, aided by productivity improvements and disciplined expense management.

Cooper Companies’ Financial PositionCOO exited the third quarter of fiscal 2026 with cash and cash equivalents of $154.7 million compared with $138.8 million at the end of the second quarter of fiscal 2026.

Total debt at the end of the fiscal third quarter was $2.54 billion compared with $2.46 billion at the end of the fiscal second quarter.

COO's Outlook for Q4 & FY26Cooper Companies has issued its outlook for the fiscal fourth quarter and updated its guidance for fiscal 2026.

For the fourth quarter of fiscal 2026, Cooper Companies expects revenues of $1.057-$1.080 billion, representing organic growth of 0-2%, and adjusted EPS of $1.05-$1.09.

CVI revenues are projected at $692-$706 million, implying organic growth of negative 2% to flat, as U.S. inventory reductions continue. CSI revenues are expected at $364-$374 million, representing organic growth of 4-6%.

For fiscal 2026, revenues are now forecast at $4.229-$4.252 billion, with adjusted EPS of $4.51-$4.55. The company expects CVI revenues of $2.828-$2.842 billion, representing organic growth of 1-2% and CSI revenues of $1.401-$1.410 billion, representing organic growth of 4-5%, while reaffirming its objective of more than $2.2 billion in cumulative free cash flow for fiscal 2026-2028.

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in estimates review.

The consensus estimate has shifted -11.07% due to these changes.

VGM ScoresCurrently, The Cooper Companies has a nice Growth Score of B, a grade with the same score on the momentum front. Charting a somewhat similar path, the stock has a score of C on the value side, putting it in the middle 20% for this investment strategy.

Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise The Cooper Companies has a Zacks Rank #5 (Strong Sell). We expect a below average return from the stock in the next few months.

Lawrence Erik Kurzius, Director at The Cooper Companies, Inc. (COO -1.90%), acquired 10,000 shares of common stock on September 14, 2026, according to a recent SEC Form 4 filing.

Premium Feature

Moneyball Superscore

66/100

Today's Change

(

-1.90

%) $

-1.07

Current Price

$

55.36

Transaction summaryMetricValueTransaction value$539,100Shares purchased10,000Post-transaction shares (directly held)21,099Post-transaction value$1.14 millionTransaction value based on SEC Form 4 weighted average purchase price ($53.91); post-transaction value based on Sept. 14, 2026 market close ($54.22).

Key questionsWhat is the scale of this acquisition relative to the insider's existing stake?
The purchase of 10,000 shares represents a 90% increase in direct ownership, expanding the position from 11,099 shares to 21,099 shares. This transaction suggests a significant expansion of the Director's direct equity commitment to the medical device company.How does the purchase price compare to the stock's recent valuation and performance?
The acquisition was completed at $53.91 per share, which was slightly below the $54.22 market close on the transaction date. As of the Sept. 15, 2026 market close, the stock was priced at $53.27, following a 19% decline in value over the 12 months ending on the trade date.Does the insider maintain any indirect or derivative exposure to the company?
The filing indicates that all 21,099 shares are held directly by Lawrence Erik Kurzius, with no reported indirect holdings through trusts or other entities. Total beneficial ownership is comprised entirely of these direct common stock holdings, with no derivative securities disclosed in this transaction.Company OverviewMetricValueShare Price (as of market close 2026-09-15)$53.27Market Capitalization$10.4 billionRevenue (TTM)$4.2 billionNet Income (TTM)$570.3 millionCompany SnapshotThe Cooper Companies develops, manufactures, and distributes a comprehensive portfolio of vision care and surgical products through two primary business units: CooperVision, which specializes in contact lenses, including spherical, toric, multifocal, and myopia management solutions, and CooperSurgical, which provides surgical instruments and supplies for ophthalmic and women's health procedures.The company generates revenue through the sale of contact lens products, surgical instruments, and related healthcare supplies to eye care professionals, surgical centers, and healthcare providers globally, leveraging a diversified product portfolio across multiple therapeutic categories and geographic markets.The Cooper Companies serves eye care practitioners, ophthalmologists, surgical centers, and healthcare institutions worldwide, with particular focus on patients requiring vision correction solutions and healthcare providers performing ophthalmic and women's health surgical procedures.The Cooper Companies is a global medical device manufacturer with approximately 15,000 employees and a market capitalization of $10.4 billion, generating $4.2 billion in trailing twelve-month (TTM) revenue. The company maintains a competitive position in the vision care and surgical markets through its dual-business-unit structure, offering both consumer-facing contact lens products and professional-grade surgical instruments that address substantial global demand for vision correction and surgical solutions.

What this transaction means for investorsKurzius is an independent director of the company. He also serves as CEO of McCormick & Co (MCK -0.48%), so he knows what the market is looking for in a publicly traded company. It's bullish that he is buying shares.

CooperCompanies is one of the largest eyecare companies in the U.S, and one of the four dominant businesses in contact lenses. Cooper was considering spinning off or selling its surgical unit, but opted to keep it in-house. That's a sign that they believe there is more value to owning the business ahead. For the current fourth quarter of its fiscal year, the company expects consolidated revenue of $1.057 billion to $1.08 billion, representing organic growth of 0% to 2%. That's not great, but management believes it sets the stage for a better 2027.

The lack of a spin-off disappointed a lot of investors and is the reason for the stock's slump of late. Kurzius' buying here has the hallmarks of a buy-low move. After all, there are many reasons an insider may sell a company's shares. One reason could be the need to raise cash to fund a large personal expense. Another reason could be for a reasonable portfolio diversification unrelated to their outlook for the company. A third reason could be what investors fear most: a bearish outlook on the company's future.

However, there is only one reason an insider buys stock: they believe the share price is going up.

By that investor's rule of thumb, Kurzius's purchase of Cooper Companies's shares is inherently bullish.

On top of that, studies show that, more often than not, an insider purchase predicts a higher share price 30 days later.

Insider buying like this is a signal to investors to take a closer look at a stock like COO and decide if it fits with their long-term investment plan. Evidently, it fits with Kurzius'.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of The Cooper Companies, Inc. (“Cooper” or the “Company”) (NASDAQ: COO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Cooper and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 9, 2026, Cooper announced third quarter 2026 results. Among other things, the Company “reported revenue of $717 million, essentially flat year-over-year” and said that “the results in the Americas reflected CooperVision’ U.S. channel inventory reductions.” The Company further stated that it “proactively reduced U.S. channel inventory that weighed on our results and will continue to impact Q4.” Cooper also lowered its full-year guidance, explaining that “the entire reason for the reduction in the revenue guidance for CooperVision was tied to just channel inventory.” Cooper also reduced revenue guidance by approximately 1.4%, or $59.5 million at the midpoint, to $4.24 billion, and likewise reduced EPS guidance by approximately 1.8%, or $0.09 at the midpoint, to a range of $4.51 to $4.55. 

On this news, Cooper’s stock price fell $9.31 per share, or 14.67%, to close at $54.17 per share on September 10, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

, /PRNewswire/ -- Investors in The Cooper Companies, Inc. (NASDAQ: COO) saw the price of their shares trade down $9.31 (-14.6%) after the company reported Q3 2026 financial results that included revelations of its U.S. channel inventory destocking along with other negative surprises. The stock's move lower wiped out over $1.7 billion of the company's market capitalization.

The revelations have prompted national shareholders rights firm Hagens Berman to open an investigation into whether The Cooper Companies was sufficiently transparent beforehand about its sales practices and, if not, whether it may have violated the securities laws.

The firm encourages Cooper investors who suffered substantial losses to submit your losses now. Persons with knowledge who may be able to assist the investigation are invited to contact the firm's attorneys.

Visit: www.hbsslaw.com/coo 

The Cooper Companies (COO) Investigation

Cooper is a global medical device company with two reporting segments. The largest – CooperVision - manufactures and markets hydrogel lens products for contact lens wearers and accounted for roughly 67% of Cooper's total consolidated sales in fiscal 2025.

The investigation is focused on the propriety of Cooper's statements about the mechanics contributing to CooperVision's revenue growth and its sustainability.

During Cooper's June 4, 2026 Q2 2026 earnings call, management emphasized CooperVision's "solid quarter, with revenues increasing 8%, or 4% organically" and guided for CooperVision full year organic revenue growth of 3.5% to 4.5%, emphasizing that "[f]or CooperVision […] [o]utside of Asia Pac, demand remains solid for premium products, including daily silicone hydrogel lenses as well as torics and multifocals."

The next day, the price of Cooper shares traded almost 8% higher.

Investors received some troubling news on September 9, 2026, when the company reported its Q3 2026 financial results. In particular, Cooper's management revealed "our legacy hydrogels were down double-digit across the board[,]" "the results in the Americas reflected CooperVision's US channel inventory reductions[,]" and "[w]e expect CooperVision revenue of $692 million to $706 million down 2% to flat organically." 

In response to an analyst's question during the earnings call about whether the entirety of the reduced guide for CooperVision revenue was inventory-related, CEO Albert White III said, "it's all destock […] [m]eaning the entire reason for the reduction in the revenue guidance for CooperVision was tied to just channel inventory."

Another analyst expressed concern, asking "why are they destocking […] [d]id you guys have too much inventory in the channel from past efforts to kind of prop up numbers?"

The market did not take kindly to the developments and sent the price of Coopers shares down over 14% the next day to close at a 52-week low of $54.17, with several analysts reportedly downgrading their ratings and price targets.

"We're focused on whether Cooper was sufficiently transparent to investors about its CooperVision sales strategies," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.

If you invested in Cooper and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now »

Whistleblowers: Persons with non-public information regarding Cooper should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.

About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

SOURCE Hagens Berman Sobol Shapiro LLP

Activist investor Jana Partners on Friday urged Cooper Companies (COO.O) to launch an external search for a new CEO and consider ​asset sales, arguing recent missteps have hurt investor ‌confidence and weighed on the medical device maker's market value.

Cooper had lowered its annual forecasts last week and ended a review of options for its ​CooperSurgical unit without a sale.

Here are more details:

Jana asked Cooper ​to engage potential buyers for its contact lens ⁠unit, CooperVision, and consider a sale of fertility and medical ​device businesses within its CooperSurgical unit.

Cooper did not immediately ​respond to a Reuters request for comment.

The activist investor owns about 3.58 million shares, or 1.8% stake, in Cooper, according to its ​latest regulatory filing.

JANA is also calling for a new board chair ​and the addition of directors with expertise to strengthen oversight of the ‌company.

Jana ⁠urged Cooper to link executive pay more closely to performance to boost accountability.

It also criticized Cooper's handling of excess inventory held by customers of CooperVision.

Jana said Cooper's shares have lagged ​peers and trade ​at a ⁠discount to comparable companies.

Shares have fallen about 21% over the past 12 months, compared ​with gains of about 19% for Becton ​Dickinson and ⁠61% for Integer Holdings and a decline of about 17% for Alcon, according to data compiled by LSEG.

The investor ⁠also ​urged Cooper to hire an outside ​adviser to identify manufacturing and supply-chain cost savings at CooperVision.

Board Unanimously Concludes to Retain CooperSurgical 

Expands Share Repurchase Authorization from $2 billion to $3 billion

Board Remains Open to All Value Options that Create Shareholder Value

SAN RAMON, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- CooperCompanies today announced the completion of its strategic review process first announced in December 2025. The comprehensive process focused on identifying opportunities to enhance long-term shareholder value including a review of the Company's portfolio, capital allocation priorities, strategic alternatives, corporate structure, leadership, operations, and strategy. As part of the process, the Board evaluated the sale of CooperSurgical. Following a thorough evaluation of strategic alternatives involving numerous parties, the Board unanimously concluded that shareholders would be better served by continued ownership than by pursuing a transaction at this time. The Board believes certain temporary factors impacted the perceived valuation at the end of the process, including recent updates regarding a competitive entrant to the non-hormonal IUD market and the impact of the Company’s recent fertility litigation settlement. The Board and its advisors believe these items contributed to a valuation disconnect whereby offers received were not in the best interest of shareholders.

“Our fiduciary duty is to maximize shareholder value, and the Board is collectively aligned that given the offers received, retaining CooperSurgical is the best path forward to creating shareholder value at this time,” said Colleen Jay, Chair of the Board. “We, with our advisors, ran an extensive process assessing a comprehensive array of strategic alternatives to enhance shareholder value and we believe that with the changes made, including a revised capital allocation strategy to capitalize on the Company’s strong free cash flow, new operational initiatives to drive organic growth at CooperVision, and a continued focus on driving fertility growth and leverage within CooperSurgical, the Company is well-positioned for future success. At the same time, we will always remain open to value creating alternatives and pursue any option that is in the best interest of our shareholders.”

Stock Buyback Program

Following completion of the strategic review, the Board reaffirmed that consistent share repurchases are an important tool to enhance shareholder value. Additionally, the Board continues to believe the Company's current valuation does not reflect the strength of its market positions, long-term growth opportunities, cash generation profile and innovation pipeline. Reflecting confidence in its intrinsic value relative to its recent valuation, the Company repurchased $445 million of shares this current fiscal year and the Board authorized an expansion of the share repurchase program from $2 billion to $3 billion to support future purchases.

Beyond stock repurchases, investments in CooperVision that prioritize commercial strengths, innovation, and organic growth will remain the top priority. CooperSurgical will prioritize organic growth initiatives and operational performance improvements.

Strengthened Board and Governance

Following constructive engagement with its shareholders, the Company enhanced the composition of its Board during the strategic review process through the addition of two new independent directors with extensive healthcare, operational and capital allocation expertise as CEOs of medical device companies. The Board believes these changes further strengthen oversight, align with shareholder feedback and support the Company's continued focus on long-term shareholder value creation. The Board remains committed to maintaining strong governance practices and regularly evaluating opportunities to further enhance its effectiveness and alignment with shareholder interests.

New Growth Investments & Operational Excellence

“Over the past year, we conducted a rigorous review of every aspect of our business with a singular focus on unlocking value,” said Al White, President and CEO of CooperCompanies. “The process identified meaningful opportunities to enhance execution, sharpen our strategic focus and accelerate innovation. We have proactively taken steps to address these items and are in the process of evaluating additional options. Looking ahead, we will continue pursuing the most value-accretive options available to us.”

Operational and organizational changes identified by the Company over the course of the strategic review include:

 (i)Enhanced Commercial Execution: The Company evaluated opportunities to strengthen commercial execution and is expanding CooperVision’s global sales and marketing organization.    (ii)Operational Excellence: The Company is actively working on continuous improvement opportunities to optimize operations including cost reduction and efficiency programs.    (iii)Revised Inventory and Logistics Approach: The Company is implementing several inventory and logistics initiatives designed to improve customer service, support future direct shipping capabilities and enhance operational efficiency.    (iv)Launch of Robust Innovation Strategy: The Company accelerated New Product Introductions, with a focus on maintaining and strengthening its leading position in the global contact lens market. Supporting this, the Company announced the grand opening of The Vision Centre, CooperVision’s new global R&D innovation hub, on September 23, 2026.   The Company expects to provide additional updates on its operational initiatives, capital allocation priorities and growth investments over the coming quarters and remains focused on identifying opportunities to enhance revenue growth, expand profitability, and increase shareholder value.

CooperCompanies Q3 2026 Earnings Results

In a separate press release today, CooperCompanies announced its financial results for the third quarter of 2026. The Company will host an audio webcast for the public, investors, analysts and news media to discuss its third quarter results, the conclusion of its strategic review and other current corporate developments. The audio webcast will be broadcast live on CooperCompanies' website, https://investor.coopercos.com, at approximately 5:00 PM ET. It will also be available for replay on CooperCompanies' website, https://investor.coopercos.com. Alternatively, you can dial in to the conference call at 800-715-9871; conference ID 9708839.

About CooperCompanies

CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life’s beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women’s healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.

Forward-Looking Statements

This press release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to plans, prospects, goals, strategies, future actions, events or performance and other statements of which are other than statements of historical fact are forward looking. In addition, all statements regarding anticipated growth in our revenues, expected savings from reorganization activities, anticipated effects of any product recalls, anticipated market conditions, planned product launches, restructuring or business transition expectations, regulatory plans, and expected results of operations and integration of any acquisition are forward-looking. To identify these statements look for words like “believes,” “outlook,” “probable,” “expects,” “may,” “will,” “should,” “could,” “seeks,” “intends,” “plans,” “estimates” or “anticipates” and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties.

Among the factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements are: adverse changes in the global or regional general business, political and economic conditions including the impact of continuing uncertainty and instability of certain countries, man-made or natural disasters and pandemic conditions, that could adversely affect our global markets, and the potential adverse economic impact and related uncertainty caused by these items; the impact of international conflicts, including the ongoing conflict in the Middle East, and the global response to international conflicts on the global and local economy, financial markets, energy markets, currency rates and our ability to supply product to, or through, or around, affected countries; our substantial and expanding international operations and the challenges of managing an organization spread throughout multiple countries and complying with a variety of legal, compliance and regulatory requirements; the actual imposition or threats of tariffs, customs duties and fees by the U.S. government and other nations in response and other retaliatory actions, such as trade protection measures, import or export licensing requirements, new or different customs duties, trade embargoes and sanctions and other trade barriers, as well as the impact of the Company’s efforts to mitigate the effects of such tariffs or similar measures; foreign currency exchange rate and interest rate fluctuations including the risk of fluctuations in the value of foreign currencies or interest rates that would decrease our net sales and earnings; our existing and future variable rate indebtedness and associated interest expense is impacted by rate increases, which could adversely affect our financial health or limit our ability to borrow additional funds; changes in tax laws, examinations by tax authorities, and changes in our geographic composition of income; acquisition-related adverse effects including the failure to successfully achieve the anticipated net sales, margins and earnings benefits of acquisitions, integration delays or costs and the requirement to record significant adjustments to the preliminary fair value of assets acquired and liabilities assumed within the measurement period, required regulatory approvals for an acquisition not being obtained or being delayed or subject to conditions that are not anticipated, adverse impacts of changes to accounting controls and reporting procedures, contingent liabilities or indemnification obligations, increased leverage and lack of access to available financing (including financing for the acquisition or refinancing of debt owed by us on a timely basis and on reasonable terms); compliance costs and potential liability in connection with U.S. and foreign laws and health care regulations pertaining to privacy and security of personal information such as the Health Insurance Portability and Accountability Act of 1996 and the California Consumer Privacy Act in the U.S. and the General Data Protection Regulation requirements in Europe, including but not limited to those resulting from data security breaches; a major disruption in the operations of our manufacturing, accounting and financial reporting, research and development, distribution facilities or raw material supply chain due to challenges associated with integration of acquisitions, man-made or natural disasters, pandemic conditions, cybersecurity incidents or other causes; a major disruption in the operations of our manufacturing, accounting and financial reporting, research and development or distribution facilities due to the failure to perform by third-party vendors, including cloud computing providers or other technological problems, including any related to our information systems maintenance, enhancements or new system deployments, integrations or upgrades; a successful cybersecurity attack which could interrupt or disrupt our information technology systems, or those of our third-party service providers, or cause the loss of confidential or protected data; market consolidation of large customers globally through mergers or acquisitions resulting in a larger proportion or concentration of our business being derived from fewer customers; disruptions in supplies of raw materials, particularly components used to manufacture our silicone hydrogel lenses; new U.S. and foreign government laws and regulations, and changes in existing laws, regulations and enforcement guidance, which affect areas of our operations including, but not limited to, those affecting the health care industry, including the contact lens industry specifically and the medical device or pharmaceutical industries generally, including but not limited to the EU Medical Devices Regulation (MDR) and the EU In Vitro Diagnostic Medical Devices Regulation; legal costs, insurance expenses, settlement costs and the risk of an adverse decision, prohibitive injunction or settlement related to product liability, patent infringement, contractual disputes, or other litigation; limitations on sales following product introductions due to poor market acceptance; new competitors, product innovations or technologies, including but not limited to, technological advances by competitors, new products and patents attained by competitors, and competitors' expansion through acquisitions; reduced sales, loss of customers, reputational harm and costs and expenses, including from claims and litigation related to product recalls and warning letters; failure to receive, or delays in receiving, regulatory approvals or certifications for products; failure of our customers and end users to obtain adequate coverage and reimbursement from third-party payers for our products and services; the requirement to provide for a significant liability or to write off, or accelerate depreciation on, a significant asset, including goodwill, other intangible assets and idle manufacturing facilities and equipment; the success of our research and development activities and other start-up projects; dilution to earnings per share from acquisitions or issuing stock; impact and costs incurred from changes in accounting standards and policies; risks related to environmental laws and requirements applicable to our facilities, products or manufacturing processes, including evolving regulations regarding the use of hazardous substances or chemicals in our products; risks related to environmental, social and corporate governance issues, including those related to regulatory and disclosure requirements, climate change and sustainability; and other events described in our United States Securities and Exchange Commission filings, including the “Business”, “Risk Factors” and “Management's Discussion and Analysis of Financial Condition and Results of Operations” sections in the Company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2025, as such Risk Factors may be updated in annual and quarterly filings.

We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any obligation to update or revise them except as required by law.

Contact:

Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663
[email protected]

SAN RAMON, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal third quarter ended July 31, 2026.

Revenue increased 1% year-over-year to $1.066 billion, including 1% organic growth.GAAP diluted earnings per share (EPS) of $2.24, compared with $0.49 in last year's third quarter, primarily driven by a $307.2 million discrete tax benefit resulting from the favorable completion of a U.K. tax examination.Non-GAAP diluted EPS of $1.15, up 4% from last year's third quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below.Free cash flow increased 66% to $273.0 million; repurchased $339.1 million of common stock.Completed the Company's strategic review process and announced actions to enhance shareholder value; additional details provided in a separate press release issued today. "This quarter included a number of notable developments including earnings exceeding expectations, record free cash flow, solid fertility growth at CooperSurgical, and a favorable completion of a significant tax matter. At CooperVision, however, we reduced U.S. channel inventory that weighed on our results and will continue to impact Q4," said Al White, President and CEO of CooperCompanies. "Following the completion of the strategic review, we are focused on profitable growth, strong cash flow generation, disciplined capital allocation, and maximizing long-term shareholder value."

Third Quarter Operating Results

Revenue of $1.066 billion, up 1% from last year’s third quarter on a reported basis, up 1% in constant currency, and up 1% organically.Gross margin of 67% compared with 65% in last year's third quarter driven by fiscal 2025 inventory write-offs related to a product line exit at CooperSurgical. On a non-GAAP basis, gross margin was 67%, down 60 basis points year-over-year, driven by higher manufacturing costs and unfavorable foreign exchange.Operating margin of 21% compared with 17% in last year’s third quarter, driven by lower operating expenses, as well as fiscal 2025 inventory and long-lived asset write-offs related to a product line exit at CooperSurgical. On a non-GAAP basis, operating margin increased 30 basis points to 26%, driven by expense management and productivity initiatives, partially offset by unfavorable foreign exchange.Interest expense of $21.5 million compared with $25.4 million in last year's third quarter driven by lower interest rates and lower average debt. On a non-GAAP basis, interest expense was $21.5 million compared with $24.7 million in the prior year period.Free cash flow of $273.0 million, up 66% from last year's third quarter, reflecting cash provided by operations of $341.7 million less capital expenditures of $68.7 million. Third Quarter CooperVision (CVI) Revenue

Revenue of $717.0 million, comparable to last year’s third quarter on a reported, constant currency, and organic basis.Revenue by category:     % change y/y  (In millions)
3Q26 Reported Currency
Impact Constant Currency Acquisitions
and
Divestitures Organic        Toric and multifocal$363.8 1% 1% 2% —% 2% Sphere, other 353.2 (2)% 1% (1)% —% (1)% Total$717.0 —% —% —% —% —%               Revenue by geography:     % change y/y  (In millions)
3Q26 Reported Currency
Impact Constant Currency Acquisitions
and
Divestitures Organic        Americas$281.6 (2)% —% (2)% —% (2)% EMEA 309.4 6% (1)% 5% —% 5% Asia Pacific 126.0 (10)% 5% (5)% —% (5)% Total$717.0 —% —% —% —% —%               Third Quarter CooperSurgical (CSI) Revenue

Revenue of $349.2 million, up 2% from last year's third quarter on a reported basis, up 2% in constant currency, and up 3% organically.Revenue by category:     % change y/y  (In millions)
3Q26 Reported Currency
Impact Constant Currency Acquisitions
and
Divestitures Organic        Office and surgical$208.0 2% —% 2% —% 2% Fertility 141.2 3% 1% 4% 1% 5% Total$349.2 2% —% 2% 1% 3%               Other

During the third quarter, the Company repurchased $339.1 million of common stock, approximately 4.9 million shares, at an average share price of $69.16. Following the Board's approval of an expansion of the share repurchase authorization from $2 billion to $3 billion, approximately $1.5 billion remains available under the program.The Company recognized a $307.2 million discrete tax benefit following the favorable completion of the related tax authority's (HMRC) examination of its fiscal 2021 transfer of intellectual property and related assets to the United Kingdom. The benefit was the primary driver of the lower GAAP effective tax rate for the quarter. Fiscal Year 2026 Financial Guidance

The Company updated its fiscal year 2026 financial guidance. Details are summarized as follows:

Fiscal fourth quarter 2026 total revenue of $1.057 - $1.080 billion (organic growth of 0% to 2%) CVI revenue of $692 -$706 million (organic growth of -2% to 0%)CSI revenue of $364 - $374 million (organic growth of 4% to 6%) Fiscal fourth quarter 2026 non-GAAP diluted EPS of $1.05 -$1.09Fiscal 2026 total revenue of $4.229 - $4.252 billion (organic growth of 2% to 3%) CVI revenue of $2.828 - $2.842 billion (organic growth of 1% to 2%)CSI revenue of $1.401 - $1.410 billion (organic growth of 4% to 5%) Fiscal 2026 non-GAAP diluted EPS of $4.51 - $4.55Reaffirm previously communicated long-term free cash flow objective exceeding $2.2 billion for fiscal years 2026 through 2028 Non-GAAP diluted earnings per share guidance excludes amortization and impairment of intangible assets, and certain income or gains and charges or expenses including acquisition and integration costs which we may incur as part of our continuing operations.

With respect to the Company’s guidance expectations, the Company has not reconciled non-GAAP diluted earnings per share guidance to GAAP diluted earnings per share due to the inherent difficulty in forecasting acquisition-related, integration and restructuring charges and expenses, which are reconciling items between the non-GAAP and GAAP measures. Due to the unknown effect, timing and potential significance of such charges and expenses that impact GAAP diluted earnings per share, the Company is not able to provide such guidance.

Reconciliation of Selected GAAP Results to Non-GAAP Results

To supplement our financial results and guidance presented on a GAAP basis, we provide non-GAAP measures such as non-GAAP gross margin, non-GAAP operating margin, non-GAAP diluted earnings per share, as well as constant currency and organic revenue growth because we believe they are helpful for the investors to understand our consolidated operating results. Management uses supplemental non-GAAP financial measures internally to understand, manage and evaluate our business, to make operating decisions, and to plan and forecast for future periods. The non-GAAP measures exclude costs which we generally would not have otherwise incurred in the periods presented as a part of our continuing operations. We provide further details of the non-GAAP adjustments made to arrive at our non-GAAP measures in the GAAP to non-GAAP reconciliations below. Our non-GAAP financial results and guidance are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP.

To present constant currency revenue growth, current period revenue for entities reporting in currencies other than the United States dollar are converted into United States dollars at the average foreign exchange rates for the corresponding period in the prior year. To present organic revenue growth, we excluded the effect of foreign currency fluctuations and the impact of any acquisitions, divestitures and discontinuations that occurred in the comparable period.

We define the non-GAAP measure of free cash flow as cash provided by operating activities less capital expenditures. We believe free cash flow is useful for investors as an additional measure of liquidity because it represents cash that is available to grow the business, make strategic acquisitions, repay debt, or buyback common stock. Management uses free cash flow internally to understand, manage, make operating decisions and evaluate our business. In addition, we use free cash flow to help plan and forecast future periods.

Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.

THE COOPER COMPANIES, INC. AND SUBSIDIARIES GAAP to Non-GAAP ReconciliationGross Margin, Operating Margin, and EPS  Three Months Ended July 31,Nine Months Ended July 31,(In millions) 2026 Margin % 2025 Margin % 2026 Margin % 2025 Margin %GAAP Gross Profit$711.9 67%$692.0 65%$2,142.5 68%$2,031.3 67%Acquisition and integration-related charges(1) (1.4)—% 4.9 1% (1.4)—% 8.7 —%Exit of business(2) — —% 15.8 1% 1.8 —% 15.8 1%Medical device regulations(3) 0.6 —% 0.7 —% 2.0 —% 2.0 —%Total (0.8)—% 21.4 2% 2.4 —% 26.5 1%Non-GAAP Gross Profit$711.1 67%$713.4 67%$2,144.9 68%$2,057.8 68%  Three Months Ended July 31,Nine Months Ended July 31,(In millions) 2026 Margin % 2025 Margin % 2026  Margin % 2025 Margin %GAAP Operating Income$222.0 21%$175.7 17%$403.8  13%$542.5 18%Amortization of acquired intangibles 47.0 4% 50.0 5% 142.6  4% 149.4 5%Acquisition and integration-related charges(1) (1.4)—% 13.6 1% (1.4) —% 27.5 1%Exit of business(2) — —% 27.2 3% 1.8  —% 27.2 1%Medical device regulations(3) 2.6 —% 4.8 —% 9.5  —% 15.5 —%Business optimization charges(4) 1.1 —% 2.7 —% 4.1  —% 2.7 —%Other(5) 9.4 1% 2.4 —% 292.9  10% 3.0 —%Total 58.7 5% 100.7 9% 449.5  14% 225.3 7%Non-GAAP Operating Income$280.7 26%$276.4 26%$853.3  27%$767.8 25%  Three Months Ended July 31,Nine Months Ended July 31,(In millions, except per share amounts) 2026 EPS 2025 EPS 2026 EPS 2025 EPSGAAP Net Income$432.8 $2.24 $98.3 $0.49 $485.7 $2.49 $290.3 $1.45 Amortization of acquired intangibles 47.0  0.24  50.0  0.25  142.6  0.73  149.4  0.74 Acquisition and integration-related charges(1) (1.4) (0.01) 13.6  0.07  (1.4) (0.01) 27.5  0.14 Exit of business(2) —  —  27.2  0.14  1.8  0.01  27.2  0.14 Medical device regulations(3) 2.6  0.01  4.8  0.02  9.5  0.05  15.5  0.07 Business optimization charges(4) 1.1  0.01  2.7  0.01  4.1  0.02  2.7  0.01 Other(5) 10.3  0.05  4.0  0.02  295.5  1.51  23.9  0.12 Tax effects related to the above items (4.6) (0.02) (26.3) (0.13) (75.2) (0.38) (52.1) (0.26)Intra-entity asset transfers(6) (266.3) (1.37) 46.0  0.23  (186.7) (0.96) 113.8  0.57 Total (211.3) (1.09) 122.0  0.61  190.2  0.97  307.9  1.53 Non-GAAP Net Income$221.5 $1.15 $220.3 $1.10 $675.9 $3.46 $598.2 $2.98 Weighted average diluted shares used 193.4   200.0   195.2   200.6                    EPS, amounts and percentages may not sum or recalculate due to rounding.

(1) Charges included $(1.4) million of facility rationalization costs adjustment related to Cook Medical integration expenses in the three and nine months ended July 31, 2026.

Charges included $5.0 million and $5.0 million of long-lived asset write-offs related to lease abandonment, $3.7 million and $5.5 million of facility rationalization costs, $3.0 million and $7.8 million related to redundant personnel costs for transitional employees, $1.2 million and $3.3 million of inventory fair value step-up amortization, $0.3 million and $2.7 million of professional services fees, and $0.4 million and $0.8 million of other acquisition and integration-related activities in the three and nine months ended July 31, 2025, respectively. The nine months ended July 31, 2025 also included $2.4 million of acquisition-related non-cash cumulative true-up adjustments reflecting changes in compensation. The acquisition and integration-related charges in fiscal 2025 were primarily related to the obp Surgical and Cook Medical acquisition and integration expenses.

Charges in this category may include the direct effects of acquisition accounting, such as amortization of inventory fair value step-up, professional services fees, regulatory fees, and items related to integrating acquired businesses, such as redundant personnel costs for transitional employees, acquisition-related non-cash cumulative true up adjustments reflecting changes in compensation, other acquisition-related costs, integration-related professional services, long-lived asset write-offs, manufacturing integration costs, legal entity and facility rationalization, and other integration-related activities.

(2) There were no charges related to the exit of business in the three months ended July 31, 2026. The nine months ended July 31, 2026 included $1.7 million of specifically-identified long-lived asset write-offs and $0.1 million of other costs related to product line exits.

Charges included $12.7 million of inventory write-offs, $14.3 million of specifically-identified long-lived asset write-offs and $0.2 million of other costs related to product line exits in the three and nine months ended July 31, 2025.

Charges in this category may include costs related to product line exits such as inventory write-offs, employee severance costs, specifically-identified long-lived asset write-offs, and other costs related to product line exits.

(3) Charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations and the E.U. in vitro diagnostic medical device regulation (collectively, the "Medical device regulations") for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be limited to a specific time period.

(4) Charges included $1.1 million and $3.4 million of redundant personnel costs for transitional employees in the three and nine months ended July 31, 2026. The nine months ended July 31, 2026 also included $0.4 million of employee severance costs and $0.3 million of other business optimization charges.

Charges included $2.7 million of employee severance costs in the three and nine months ended July 31, 2025.

Charges in this category represent costs associated with initiatives to increase efficiency and optimize the cost structure, and may include, among other items, changes to our IT infrastructure and operations, employee severance costs, redundant personnel costs for transitional employees, legal entity and other business reorganizations, and inventories associated with the business optimization activities.

(5) Charges included $2.2 million and $274.4 million related to litigation expense and associated legal costs, $2.9 million and $14.1 million related to legal matters, $4.3 million and $4.3 million related to strategic review costs, and $0.9 million and $2.7 million of gains and losses on minority interest investments in the three and nine months ended July 31, 2026.

Charges included $2.4 million and $3.0 million related to legal matters, $0.9 million and $18.8 million of gains and losses on a minority interest investment, and $0.7 million and $2.1 million of accretion of interest attributable to acquisition installment payable in the three and nine months ended July 31, 2025. The gains and losses on the minority interest investment for the nine months ended July 31, 2025 included a $15.7 million loss on the disposal of a minority interest investment.

Charges in this category may include legal matters, litigation expense, strategic review costs, and other items that are not part of ordinary operations. The adjustments to arrive at non-GAAP net income also include gains and losses on minority interest investments and accretion of interest attributable to acquisition installment payables.

(6) In fiscal 2021, the Company transferred its CooperVision intellectual property and related assets to its UK subsidiary. As a result, we recorded a deferred tax asset equal to approximately $2.0 billion as a one-time tax benefit in accordance with U.S. GAAP in fiscal 2021. The deferred tax asset was recorded net of a $307.2 million reserve for an uncertain tax position related to the valuation of the transferred assets.

Non-GAAP adjustments continue to reflect the recurring net deferred tax benefit associated with amortization of the transferred assets under UK tax law. In the 3rd fiscal quarter 2026, non-GAAP adjustments also include the reversal of the $307.2 million uncertain tax position following completion of the related tax authority examination with no proposed adjustments.

Audio Webcast and Conference Call

The Company will host an audio webcast today for the public, investors, analysts and news media to discuss its third quarter results, the conclusion of the strategic review and current corporate developments. The audio webcast will be broadcast live on CooperCompanies' website, www.investor.coopercos.com, at approximately 5:00 PM ET. It will also be available for replay on CooperCompanies' website, www.investor.coopercos.com. Alternatively, you can dial in to the conference call at 800-715-9871; conference ID 9708839.

About CooperCompanies

CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.

Forward-Looking Statements

This earnings release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, future actions, events or performance and other statements of which are other than statements of historical fact, including our fiscal year 2026 financial guidance, are forward looking. In addition, all statements regarding anticipated growth in our revenues, expected savings from reorganization activities, anticipated effects of any product recalls, anticipated market conditions, planned product launches, restructuring or business transition expectations, regulatory plans, and expected results of operations and integration of any acquisition are forward-looking. To identify these statements look for words like "believes," "outlook," "probable," "expects," "may," "will," "should," "could," "seeks," "intends," "plans," "estimates" or "anticipates" and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties.

Among the factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements are: adverse changes in the global or regional general business, political and economic conditions including the impact of continuing uncertainty and instability of certain countries, man-made or natural disasters and pandemic conditions, that could adversely affect our global markets, and the potential adverse economic impact and related uncertainty caused by these items; the impact of international conflicts, including the ongoing conflict in the Middle East, and the global response to international conflicts on the global and local economy, financial markets, energy markets, currency rates and our ability to supply product to, or through, or around, affected countries; our substantial and expanding international operations and the challenges of managing an organization spread throughout multiple countries and complying with a variety of legal, compliance and regulatory requirements; the actual imposition or threats of tariffs, customs duties and fees by the U.S. government and other nations in response and other retaliatory actions, such as trade protection measures, import or export licensing requirements, new or different customs duties, trade embargoes and sanctions and other trade barriers, as well as the impact of the Company’s efforts to mitigate the effects of such tariffs or similar measures; foreign currency exchange rate and interest rate fluctuations including the risk of fluctuations in the value of foreign currencies or interest rates that would decrease our net sales and earnings; our existing and future variable rate indebtedness and associated interest expense is impacted by rate increases, which could adversely affect our financial health or limit our ability to borrow additional funds; changes in tax laws, examinations by tax authorities, and changes in our geographic composition of income; acquisition-related adverse effects including the failure to successfully achieve the anticipated net sales, margins and earnings benefits of acquisitions, integration delays or costs and the requirement to record significant adjustments to the preliminary fair value of assets acquired and liabilities assumed within the measurement period, required regulatory approvals for an acquisition not being obtained or being delayed or subject to conditions that are not anticipated, adverse impacts of changes to accounting controls and reporting procedures, contingent liabilities or indemnification obligations, increased leverage and lack of access to available financing (including financing for the acquisition or refinancing of debt owed by us on a timely basis and on reasonable terms); compliance costs and potential liability in connection with U.S. and foreign laws and health care regulations pertaining to privacy and security of personal information such as the Health Insurance Portability and Accountability Act of 1996 and the California Consumer Privacy Act in the U.S. and the General Data Protection Regulation requirements in Europe, including but not limited to those resulting from data security breaches; a major disruption in the operations of our manufacturing, accounting and financial reporting, research and development, distribution facilities or raw material supply chain due to challenges associated with integration of acquisitions, man-made or natural disasters, pandemic conditions, cybersecurity incidents or other causes; a major disruption in the operations of our manufacturing, accounting and financial reporting, research and development or distribution facilities due to the failure to perform by third-party vendors, including cloud computing providers or other technological problems, including any related to our information systems maintenance, enhancements or new system deployments, integrations or upgrades; a successful cybersecurity attack which could interrupt or disrupt our information technology systems, or those of our third-party service providers, or cause the loss of confidential or protected data; market consolidation of large customers globally through mergers or acquisitions resulting in a larger proportion or concentration of our business being derived from fewer customers; disruptions in supplies of raw materials, particularly components used to manufacture our silicone hydrogel lenses; new U.S. and foreign government laws and regulations, and changes in existing laws, regulations and enforcement guidance, which affect areas of our operations including, but not limited to, those affecting the health care industry, including the contact lens industry specifically and the medical device or pharmaceutical industries generally, including but not limited to the EU Medical Devices Regulation (MDR) and the EU In Vitro Diagnostic Medical Devices Regulation; legal costs, insurance expenses, settlement costs and the risk of an adverse decision, prohibitive injunction or settlement related to product liability, patent infringement, contractual disputes, or other litigation; limitations on sales following product introductions due to poor market acceptance; new competitors, product innovations or technologies, including but not limited to, technological advances by competitors, new products and patents attained by competitors, and competitors' expansion through acquisitions; reduced sales, loss of customers, reputational harm and costs and expenses, including from claims and litigation related to product recalls and warning letters; failure to receive, or delays in receiving, regulatory approvals or certifications for products; failure of our customers and end users to obtain adequate coverage and reimbursement from third-party payers for our products and services; the requirement to provide for a significant liability or to write off, or accelerate depreciation on, a significant asset, including goodwill, other intangible assets and idle manufacturing facilities and equipment; the success of our research and development activities and other start-up projects; dilution to earnings per share from acquisitions or issuing stock; impact and costs incurred from changes in accounting standards and policies; risks related to environmental laws and requirements applicable to our facilities, products or manufacturing processes, including evolving regulations regarding the use of hazardous substances or chemicals in our products; risks related to environmental, social and corporate governance issues, including those related to regulatory and disclosure requirements, climate change and sustainability; and other events described in our United States Securities and Exchange Commission filings, including the “Business”, “Risk Factors” and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in the Company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2025, as such Risk Factors may be updated in annual and quarterly filings.

We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any obligation to update or revise them except as required by law.

Contact:

Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663
[email protected]

THE COOPER COMPANIES, INC. AND SUBSIDIARIESConsolidated Condensed Balance Sheets(In millions)(Unaudited)  July 31, 2026 October 31, 2025ASSETSCurrent assets:   Cash and cash equivalents$154.7 $110.6Trade receivables, net 788.9  829.0Inventories 911.5  846.0Prepaid expense and other current assets 426.4  320.8Total current assets 2,281.5  2,106.4Property, plant and equipment, net 2,144.9  2,082.0Goodwill 3,876.3  3,853.4Other intangibles, net 1,445.9  1,586.3Deferred tax assets 2,267.9  2,077.5Other assets 656.9  689.2Total assets$12,673.4 $12,394.8    LIABILITIES AND STOCKHOLDERS’ EQUITYCurrent liabilities:   Short-term debt$628.1 $47.8Accounts payable 251.2  300.4Employee compensation and benefits 174.6  210.6Deferred revenue 129.6  127.9Accrued litigation liability 316.5  0.7Other current liabilities 366.6  425.4Total current liabilities 1,866.6  1,112.8Long-term debt 1,916.1  2,457.5Deferred tax liabilities 94.2  93.3Long-term tax payable 2.4  7.5Deferred revenue 208.7  201.8Other liabilities 257.0  282.8Total liabilities 4,345.0  4,155.7Stockholders’ equity 8,328.4  8,239.1Total liabilities and stockholders' equity$12,673.4 $12,394.8 THE COOPER COMPANIES, INC. AND SUBSIDIARIESConsolidated Condensed Statements of Income(In millions, except per share amounts)(Unaudited)  Three Months Ended
July 31, Nine Months Ended
July 31,  2026   2025   2026   2025Net sales$1,066.2  $1,060.3  $3,171.8  $3,027.3Cost of sales 354.3   368.3   1,029.3   996.0Gross profit 711.9   692.0   2,142.5   2,031.3Selling, general and administrative expense 401.3   421.7   1,467.7   1,208.6Research and development expense 41.6   44.6   128.4   130.8Amortization of intangibles 47.0   50.0   142.6   149.4Operating income 222.0   175.7   403.8   542.5Interest expense 21.5   25.4   64.8   75.6Other (income) expense, net (1.3)  (1.6)  (6.6)  17.2Income before income taxes 201.8   151.9   345.6   449.7Provision for income taxes (231.0)  53.6   (140.1)  159.4Net income$432.8  $98.3  $485.7  $290.3        Earnings per share - diluted$2.24  $0.49  $2.49  $1.45        Number of shares used to compute diluted earnings per share 193.4   200.0   195.2   200.6                EPS, amounts and percentages may not sum or recalculate due to rounding.

THE COOPER COMPANIES, INC. AND SUBSIDIARIESGAAP to Non-GAAP ReconciliationConstant Currency Revenue Growth and Organic Revenue Growth  Net Sales   % change y/y (In millions)
3Q26 Reported Currency
Impact Constant
Currency Acquisitions
and
Divestitures Organic      CooperVision$717.0 —% —% —% —% —%CooperSurgical 349.2 2% —% 2% 1% 3%Total$1,066.2 1% —% 1% —% 1%

Key Takeaways COO's two healthcare platforms span contact lenses and fertility, reducing reliance on one end market.MyDay and MiSight drove premium growth, with MiSight revenue up 24% to $32M in fiscal Q2.Asia-Pacific softness, hydrogel exits and margin pressures keep COO's investment case measured. The Cooper Companies, Inc. (COO - Free Report) has two durable healthcare platforms, but its investment case is being shaped by execution as much as demand.

Premium contact lenses, myopia control and fertility products support growth. Asia-Pacific softness, legacy product exits and cost pressure keep the outlook measured.

Why COO’s Two-Segment Model MattersCooperVision gives COO scale in contact lenses, a category with recurring demand once patients are fitted and reorder lenses. For fiscal 2025, CooperVision generated $2.74 billion, or 67% of net sales.

CooperSurgical adds fertility, office and surgical products, reducing reliance on one end market. Its fiscal 2025 revenues were $1.35 billion, or 33% of net sales, giving COO a second healthcare growth engine.

Sales are expected to grow by more than 5% in fiscal 2026 as well as in fiscal 2027.

Image Source: Zacks Investment Research

How CooperVision Drives Premium MixThe main mix story is the migration from lower-value clariti lenses to MyDay daily silicone hydrogel lenses. MyDay delivered double-digit growth in the second quarter of fiscal 2026, while daily silicone hydrogel lenses grew 8%.

Toric and multifocal revenues rose 7% organically, supported by MyDay Energys, multifocal lenses, trial activity, practitioner engagement and broader parameter availability. Alcon Inc. (ALC - Free Report) is a relevant peer because its vision-care portfolio also includes contact lenses and ocular health, keeping competitive focus on product breadth.

Why MiSight Keeps Cooper RelevantMiSight gives CooperVision a differentiated position in pediatric myopia control, not just another lens extension. The product is the only FDA-approved daily contact lens to slow myopia progression in children.

In the second quarter of fiscal 2026, MiSight revenue grew 24% to $32 million. Japan momentum exceeded expectations, while MyDay MiSight in Europe performed well with eye-care practitioners, reinforcing a premium, clinically driven category.

COO’s Pressure PointsAsia-Pacific remains the clearest near-term drag. CooperVision’s Asia-Pacific revenue declined 6% organically to $130.6 million in the second quarter of fiscal 2026, with weakness tied to China, Japan and Korea.

The hydrogel rationalization program could pressure results into 2027. Gross margin also faces tariffs, freight, foreign exchange and lower production, with management expecting third-quarter gross margin of about 66%.

Despite the gross margin facing macro headwinds, COO’s earnings per share is estimated to improve 12.4% in fiscal 2026.

Image Source: Zacks Investment Research

How CooperSurgical Broadens the StoryCooperSurgical keeps the total thesis from depending only on vision care. In the second quarter of fiscal 2026, CSI revenue was $358 million, up 6% organically, with fertility revenue of $143.8 million rising 10% organically.

Paragard performed better than expected with flat revenue growth, while office and surgical products added stability. Bausch + Lomb Corporation (BLCO - Free Report) offers another eye-health comparison point, but COO’s fertility exposure gives it a different diversification profile.

How COO’s Rating Signals Fit the StoryThe bottom line is balanced. COO has attractive category exposure, premium product momentum and cash generation, but regional resets, litigation payouts and margin headwinds keep the investment case measured.

The stock currently carries a Zacks Rank #3 (Hold), which aligns with the Neutral recommendation. That rank points to a more wait-and-see setup rather than a clear near-term earnings revision signal. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

COO’s Style Scores are more constructive, with a VGM Score of B, Value Score of B and Growth Score of B. These scores support the view that the stock has reasonable valuation and growth characteristics. However, the Momentum Score of D suggests weaker timing support, making execution in Asia-Pacific, margin recovery and cash conversion key watch points.